Publications by authors named "Kalliopi Zachou"

Background & Aims: Liver stiffness measurement (LSM) has been shown to adequately predict outcomes in patients with liver disease. However, the value of LSM as a predictor of disease progression in autoimmune hepatitis (AIH) remains to be determined. This study aimed to evaluate the role of LSM as a predictor of disease progression and decompensation of cirrhosis in patients with AIH.

View Article and Find Full Text PDF

Background And Aims: A limited number of drugs are used as standard or alternative therapies in autoimmune hepatitis (AIH). No specific recommendations are available for patients failing to respond to these therapies. We analyzed the efficacy and safety of infliximab in patients with AIH.

View Article and Find Full Text PDF

Generalized pustular psoriasis (GPP) presents as a severe variant of psoriasis featuring painful, sterile pustules on red skin and can lead to life-threatening complications if left untreated. The disease course is typically unpredictable, with periods of improvement, followed by relapses over extended periods. Managing GPP flares is challenging due to their potential to endanger the patient's life, underscoring the need for treatments that are both fast-acting and highly effective in the case of severe and systematically ill GPP patients.

View Article and Find Full Text PDF
Article Synopsis
  • - The R-LIVER registry, initiated by the European Reference Network on Hepatological Diseases, analyzed the presentation and outcomes of autoimmune hepatitis (AIH) in 231 patients across six European centers over a year.
  • - After 6 months, 50% of patients achieved complete biochemical response (CBR), with a rise to 63% by the 12-month mark, but only 27% managed to achieve this without steroids during the first year.
  • - Results indicate significant variability in AIH treatment, with many patients experiencing treatment changes due to intolerance, and highlight the need for improved strategies given the low CBR rates and challenges in steroid withdrawal.
View Article and Find Full Text PDF
Article Synopsis
  • Detecting autoantibodies is crucial for diagnosing autoimmune hepatitis (AIH), especially in children where their specificity can be lower; recent research points to polyreactive IgG (pIgG) as a promising marker.
  • A study, using samples from multiple European centers, found that pIgG had enhanced specificity and accuracy for diagnosing pediatric AIH compared to traditional antibodies like ANA and anti-SMA.
  • pIgG distinguished AIH from other liver diseases with an AUC of 0.900, showing it was positive in a significant portion of pediatric patients and independent of their treatment response.
View Article and Find Full Text PDF

Background: Autoimmune hepatitis (AIH) is a relatively rare autoimmune disease with a strong genetic background. The patatin-like phospholipase domain-containing protein 3 () (38409 C/G) variant has been associated with hepatic inflammation and fibrosis in chronic hepatic diseases beyond metabolic dysfunction-associated steatotic liver disease (MASLD).

Aim: Our aim was to investigate the significance of variant in AIH.

View Article and Find Full Text PDF

Background And Aims: Metabolomics is used to predict, diagnose, and monitor metabolic disorders but altered metabolomic signatures have also been reported in diverse diseases, including autoimmune disorders. However, the metabolomic profile in autoimmune hepatitis (AIH) has not been investigated in depth. Therefore, we investigated the metabolomic signature of AIH and its significance as a diagnostic and pathogenetic tool.

View Article and Find Full Text PDF

Background: FibroMeter and FibroMeter vibration-controlled transient elastography (FibroMeter VCTE) were assessed in a Greek cohort of patients with chronic viral hepatitis (CVH) B and C or metabolic dysfunction-associated steatotic liver disease (MASLD) to evaluate their accuracy in predicting advanced liver fibrosis against other well-validated noninvasive markers.

Methods: Group 1: n=83 CVH and group 2: n=38 MASLD patients underwent liver biopsy and transient elastography (TE) on the same day as sera collection. FibroMeter scores APRI and FIB-4 were calculated in all 121 patients, while MASLD fibrosis score (MFS) was also calculated in group 2.

View Article and Find Full Text PDF

Background And Aims: Autoimmune hepatitis (AIH) is a rare chronic liver disease of unknown aetiology; the risk of hepatocellular carcinoma (HCC) remains unclear and risk factors are not well-defined. We aimed to investigate the risk of HCC across a multicentre AIH cohort and to identify predictive factors.

Methods: We performed a retrospective, observational, multicentric study of patients included in the International Autoimmune Hepatitis Group Retrospective Registry.

View Article and Find Full Text PDF
Article Synopsis
  • There is limited data on the safety and effectiveness of immunomodulatory drugs for treating autoimmune hepatitis (AIH), even though they are commonly used for other autoimmune conditions.
  • A survey of hepatology centers in Europe revealed 25 AIH patients, most of whom received standard AIH treatment before starting unconventional therapies to address other autoimmune diseases.
  • At the end of the follow-up period, 13 patients achieved a complete biochemical response, though some experienced relapses or insufficient response, and side effects from treatments were reported.
View Article and Find Full Text PDF

Background And Aims: We previously developed and validated a non-invasive diagnostic index based on routine laboratory parameters for predicting the stage of hepatic fibrosis in patients with chronic hepatitis C (CHC) called FIB-6 through machine learning with random forests algorithm using retrospective data of 7238 biopsy-proven CHC patients. Our aim is to validate this novel score in patients with metabolic dysfunction-associated fatty liver disease (MAFLD).

Method: Performance of the new score was externally validated in cohorts from one site in Egypt (n = 674) and in 5 different countries (n = 1798) in Iran, KSA, Greece, Turkey and Oman.

View Article and Find Full Text PDF

Background And Aims: The International Autoimmune Hepatitis Group retrospective registry (IAIHG-RR) is a web-based platform with subjects enrolled with a clinical diagnosis of autoimmune hepatitis (AIH). As prognostic factor studies with enough power are scarce, this study aimed to ascertain data quality and identify prognostic factors in the IAIHG-RR cohort.

Methods: This retrospective, observational, multicenter study included all patients with a clinical diagnosis of AIH from the IAIHG-RR.

View Article and Find Full Text PDF

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) affect 17-46% of Western countries, making coexistence with other liver diseases inevitable. We investigated the prevalence and clinical significance of NAFLD/NASH or the components of metabolic syndrome (MetS) in a large multicentric cohort of patients with autoimmune hepatitis (AIH).

Methods: Data from six academic centres (Greece, Canada, Japan, Germany, The Netherlands, and Spain) were evaluated.

View Article and Find Full Text PDF
Article Synopsis
  • * Among the 123 AMA-positive AIH patients studied, 5.1% had AMA, more commonly found in females; however, there were no significant differences in liver damage or treatment response compared to AMA-negative patients.
  • * The presence of AMA is noteworthy mainly when linked to non-specific bile duct injury, as these patients have a higher risk of progressing to cirrhosis and developing further liver damage over time, emphasizing the need for thorough liver biopsy assessments.
View Article and Find Full Text PDF

Background And Aims: Hepatitis D virus (HDV) underdiagnosis remains common. We assessed the HDV screening and prevalence rates in HBsAg-positive patients seen at tertiary liver centres throughout Greece as well as factors affecting HDV diagnosis.

Methods: All adult HBsAg-positive patients seen within the last 5 years were included.

View Article and Find Full Text PDF

Background: Portal vein thrombosis (PVT) is a common complication of cirrhosis and can be a cause or consequence of liver disease progression. It is unclear whether PVT treatment is affecting clinical outcomes in cirrhotics.

Methods: This is a multicenter study of cirrhotics with PVT, initially retrospectively and thereafter prospectively registered in a data base.

View Article and Find Full Text PDF

Background & Aims: We have shown previously that mycophenolate mofetil (MMF) might be used as first-line treatment instead of azathioprine (AZA) in individuals with autoimmune hepatitis (AIH). Herein, we present our long-term prospective data on response and outcome after first-line therapy with MMF in treatment-naïve individuals with AIH, as similar data are missing.

Methods: During the 21 years of the study, 292 individuals with AIH were included (females: 213; median age: 59 [17-85] years).

View Article and Find Full Text PDF

Background: Hepatitis E virus (HEV) infection incidence is increasing in Europe, accounting for the majority of acute hepatitis cases. We investigated the prevalence and clinical characteristics of acute hepatitis E (AHE) in patients with acute non-A/B/C hepatitis from central Greece, their differences from acute autoimmune hepatitis (AIH) patients and the molecular similarity of human strains to local HEV strains in wild boars.

Methods: Sera from 20 patients with non-A/B/C acute hepatitis (2015-2017) were tested prospectively for anti-HEV IgM, IgG antibodies and HEV-RNA.

View Article and Find Full Text PDF

HBV RNA is considered as a promising predictor in patients who discontinue nucleos(t)ide analogues (NAs). We determined HBV RNA levels in non-cirrhotic HBeAg-negative patients who discontinued NAs and assessed their predictability for 12-month outcomes. Fifty-seven patients of DARING-B study were included.

View Article and Find Full Text PDF

Background And Aims: Little is known about the impact of DNA methylation modifications on autoimmune hepatitis (AIH) pathogenesis and therapeutic response. We investigated the potential alterations of DNA methylation in AIH peripheral lymphocytes at diagnosis and remission.

Methods: Ten AIH patients at diagnosis (time-point 1; AIH-tp1), 8/10 following biochemical response (time-point 2; AIH-tp2), 9 primary biliary cholangitis (PBC) and 10 healthy controls (HC) were investigated.

View Article and Find Full Text PDF

Background/aims: As previous real-world studies and meta-analyses have shown that mycophenolate mofetil (MMF) might have better efficacy than azathioprine (AZA) in autoimmune hepatitis (AIH), we conducted a propensity matching study to assess the efficacy and safety of MMF vs. AZA.

Methods: All 126 consecutive treatment-naive adult AIH patients, diagnosed and followed in our department since 2016, were included.

View Article and Find Full Text PDF

Carbapenem-resistant Gram-negative bacteria are a public health threat that requires urgent action. The fact that these pathogens commonly also harbor resistance mechanisms for several other antimicrobial classes further reduces patient treatment options. The present study aimed to provide information regarding the multidrug resistance genetic background of carbapenem-resistant Gram-negative bacteria in Central Greece.

View Article and Find Full Text PDF

Background And Aims: Scarce data exist on the effect of nucleos(t)ide analogue (NA) discontinuation on hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe-). Therefore, we assessed whether HCC risk is increased in non-cirrhotic CHBe- patients who discontinue compared to those remaining on NAs.

Methods: This cohort study included 650 consecutive non-cirrhotic Caucasian or Asian patients with CHBe- without a history of HCC who discontinued NAs after a median of 5 or 3 years (cases, n = 325; Caucasians: 143, Asians: 182) or remained on NA therapy beyond 5 or 3 years respectively (controls, n = 325; Caucasians: 223, Asians: 102).

View Article and Find Full Text PDF

Autoimmune hepatitis (AIH) is a chronic non-resolving liver disease characterized by diffuse hypergammaglobulinemia, the presence of autoantibodies and characteristic histological findings. The disease can have catastrophic outcome with the development of end-stage liver disease if misdiagnosed/undiagnosed and left untreated. AIH pathogenesis remains obscure and the main hypothesis supports its development in genetically predisposed individuals after being exposed to certain environmental triggers.

View Article and Find Full Text PDF